Which has stronger valuation & earnings, MEDP or RMD?

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.95 $451.12M $15.91 33.13 ResMed $5.15B 5.65 $1.40B $10.37 19.33

Is MEDP or RMD more profitable?

ResMed has a net margin of 27.44% compared to Medpace's net margin of 17.19%. Medpace's return on equity of 120.89% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% ResMed 27.44% 25.35% 18.69%

Does the media refer more to MEDP or RMD?

In the previous week, ResMed had 2 more articles in the media than Medpace. MarketBeat recorded 5 mentions for ResMed and 3 mentions for Medpace. ResMed's average media sentiment score of 1.23 beat Medpace's score of 1.02 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EHC or RMD more profitable?

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity. Company Net Margins Return on Equity Return on Assets Encompass Health 10.04% 18.28% 8.27% ResMed 27.44% 25.35% 18.69%

Does the media favor EHC or RMD?

In the previous week, ResMed had 3 more articles in the media than Encompass Health. MarketBeat recorded 5 mentions for ResMed and 2 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.51 beat ResMed's score of 1.23 indicating that Encompass Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ResMed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, RMD or HIMS?

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.65 $1.40B $10.37 19.33 Hims & Hers Health $2.37B 3.31 $128.37M -$0.09 N/A

Is RMD or HIMS more profitable?

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Hims & Hers Health -0.56% 6.10% 1.52%

Does the media prefer RMD or HIMS?

In the previous week, Hims & Hers Health had 15 more articles in the media than ResMed. MarketBeat recorded 20 mentions for Hims & Hers Health and 5 mentions for ResMed. ResMed's average media sentiment score of 1.23 beat Hims & Hers Health's score of 0.58 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 8 Very Positive mention(s) 8 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, MDT or RMD?

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medtronic $36.36B 2.85 $4.80B $3.73 21.70 ResMed $5.15B 5.65 $1.40B $10.37 19.33

Is MDT or RMD more profitable?

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity. Company Net Margins Return on Equity Return on Assets Medtronic 13.20% 14.51% 7.76% ResMed 27.44% 25.35% 18.69%

Does the media favor MDT or RMD?

In the previous week, Medtronic had 26 more articles in the media than ResMed. MarketBeat recorded 31 mentions for Medtronic and 5 mentions for ResMed. Medtronic's average media sentiment score of 1.39 beat ResMed's score of 1.23 indicating that Medtronic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medtronic 23 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive ResMed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RMD or BSX?

Boston Scientific has higher revenue and earnings than ResMed. Boston Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.65 $1.40B $10.37 19.33 Boston Scientific $20.07B 3.27 $2.90B $2.39 18.48

Is RMD or BSX more profitable?

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.29%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Boston Scientific 17.29% 19.17% 10.77%

Does the media refer more to RMD or BSX?

In the previous week, Boston Scientific had 30 more articles in the media than ResMed. MarketBeat recorded 35 mentions for Boston Scientific and 5 mentions for ResMed. ResMed's average media sentiment score of 1.23 beat Boston Scientific's score of 0.91 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Boston Scientific 21 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Positive

ResMed (RMD) Competitors

$200.49 +1.89 (+0.95%)

Closing price 03:59 PM Eastern

Extended Trading

$201.96 +1.46 (+0.73%)

As of 07:40 PM Eastern

Compare

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

Should you buy ResMed stock or one of its competitors? MarketBeat compares ResMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Medtronic (MDT), and Boston Scientific (BSX). These companies are all part of the "medical" sector.

How does ResMed compare to Medpace?

Medpace (NASDAQ:MEDP) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Medpace presently has a consensus target price of $467.08, indicating a potential downside of 11.38%. ResMed has a consensus target price of $270.82, indicating a potential upside of 35.08%. Given ResMed's stronger consensus rating and higher possible upside, analysts plainly believe ResMed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, ResMed had 2 more articles in the media than Medpace. MarketBeat recorded 5 mentions for ResMed and 3 mentions for Medpace. ResMed's average media sentiment score of 1.23 beat Medpace's score of 1.02 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, ResMed has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.95	$451.12M	$15.91	33.13
ResMed	$5.15B	5.65	$1.40B	$10.37	19.33

ResMed has a net margin of 27.44% compared to Medpace's net margin of 17.19%. Medpace's return on equity of 120.89% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
ResMed	27.44%	25.35%	18.69%

Summary

ResMed beats Medpace on 9 of the 17 factors compared between the two stocks.

How does ResMed compare to Encompass Health?

Encompass Health (NYSE:EHC) and ResMed (NYSE:RMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Encompass Health presently has a consensus target price of $143.86, indicating a potential upside of 41.97%. ResMed has a consensus target price of $270.82, indicating a potential upside of 35.08%. Given Encompass Health's stronger consensus rating and higher probable upside, analysts clearly believe Encompass Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Encompass Health has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, ResMed has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

ResMed has lower revenue, but higher earnings than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$5.94B	1.69	$566.20M	$5.99	16.92
ResMed	$5.15B	5.65	$1.40B	$10.37	19.33

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.04%	18.28%	8.27%
ResMed	27.44%	25.35%	18.69%

Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Encompass Health pays out 12.7% of its earnings in the form of a dividend. ResMed pays out 23.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has raised its dividend for 2 consecutive years and ResMed has raised its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, ResMed had 3 more articles in the media than Encompass Health. MarketBeat recorded 5 mentions for ResMed and 2 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.51 beat ResMed's score of 1.23 indicating that Encompass Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ResMed	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Encompass Health shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.8% of Encompass Health shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

ResMed beats Encompass Health on 12 of the 19 factors compared between the two stocks.

How does ResMed compare to Hims & Hers Health?

ResMed (NYSE:RMD) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.65	$1.40B	$10.37	19.33
Hims & Hers Health	$2.37B	3.31	$128.37M	-$0.09	N/A

In the previous week, Hims & Hers Health had 15 more articles in the media than ResMed. MarketBeat recorded 20 mentions for Hims & Hers Health and 5 mentions for ResMed. ResMed's average media sentiment score of 1.23 beat Hims & Hers Health's score of 0.58 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	8 Very Positive mention(s)	8 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed presently has a consensus price target of $270.82, suggesting a potential upside of 35.08%. Hims & Hers Health has a consensus price target of $29.37, suggesting a potential downside of 13.28%. Given ResMed's stronger consensus rating and higher probable upside, research analysts plainly believe ResMed is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

ResMed has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market.

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Hims & Hers Health	-0.56%	6.10%	1.52%

55.0% of ResMed shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 0.7% of ResMed shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ResMed beats Hims & Hers Health on 13 of the 17 factors compared between the two stocks.

How does ResMed compare to Medtronic?

Medtronic (NYSE:MDT) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medtronic	13.20%	14.51%	7.76%
ResMed	27.44%	25.35%	18.69%

Medtronic pays an annual dividend of $2.84 per share and has a dividend yield of 3.5%. ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Medtronic pays out 76.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed pays out 23.1% of its earnings in the form of a dividend. Medtronic has increased its dividend for 49 consecutive years and ResMed has increased its dividend for 13 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$36.36B	2.85	$4.80B	$3.73	21.70
ResMed	$5.15B	5.65	$1.40B	$10.37	19.33

82.1% of Medtronic shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Medtronic had 26 more articles in the media than ResMed. MarketBeat recorded 31 mentions for Medtronic and 5 mentions for ResMed. Medtronic's average media sentiment score of 1.39 beat ResMed's score of 1.23 indicating that Medtronic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medtronic	23 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
ResMed	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medtronic currently has a consensus price target of $99.00, indicating a potential upside of 22.32%. ResMed has a consensus price target of $270.82, indicating a potential upside of 35.08%. Given ResMed's stronger consensus rating and higher probable upside, analysts plainly believe ResMed is more favorable than Medtronic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	0 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.61
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Medtronic has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, ResMed has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Summary

ResMed beats Medtronic on 11 of the 20 factors compared between the two stocks.

How does ResMed compare to Boston Scientific?

ResMed (NYSE:RMD) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 89.1% of Boston Scientific shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 0.3% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ResMed currently has a consensus target price of $270.82, indicating a potential upside of 35.08%. Boston Scientific has a consensus target price of $83.36, indicating a potential upside of 88.75%. Given Boston Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Boston Scientific is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Boston Scientific	1 Sell rating(s)	5 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.80

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.29%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Boston Scientific	17.29%	19.17%	10.77%

Boston Scientific has higher revenue and earnings than ResMed. Boston Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.65	$1.40B	$10.37	19.33
Boston Scientific	$20.07B	3.27	$2.90B	$2.39	18.48

ResMed has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Boston Scientific has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Boston Scientific had 30 more articles in the media than ResMed. MarketBeat recorded 35 mentions for Boston Scientific and 5 mentions for ResMed. ResMed's average media sentiment score of 1.23 beat Boston Scientific's score of 0.91 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Boston Scientific	21 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Positive

Summary

ResMed beats Boston Scientific on 9 of the 16 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RMD vs. The Competition

Export

Metric	ResMed	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$28.81B	$8.43B	$6.71B	$23.23B
Dividend Yield	1.21%	2.49%	2.67%	4.10%
P/E Ratio	19.33	15.91	26.03	31.64
Price / Sales	5.65	7.82	556.43	21.39
Price / Cash	17.73	17.55	46.99	24.58
Price / Book	4.93	3.36	10.77	4.74
Net Income	$1.40B	$226.25M	$3.57B	$1.07B
7 Day Performance	6.18%	0.44%	3.15%	0.99%
1 Month Performance	-3.52%	-1.88%	2.33%	0.97%
1 Year Performance	-21.83%	0.69%	33.42%	24.40%

ResMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RMD ResMed	4.8441 of 5 stars	$200.49 +1.0%	$270.82 +35.1%	-23.1%	$28.81B	$5.15B	19.33	10,600	Positive News
MEDP Medpace	2.0321 of 5 stars	$455.66 -1.0%	$467.08 +2.5%	+67.1%	$13.14B	$2.53B	28.64	6,200	Positive News
EHC Encompass Health	4.9022 of 5 stars	$98.55 +0.5%	$143.86 +46.0%	-17.7%	$9.72B	$5.94B	16.45	42,000	Positive News
HIMS Hims & Hers Health	2.4779 of 5 stars	$33.60 -5.3%	$29.37 -12.6%	-20.8%	$8.21B	$2.35B	N/A	2,442	Trending News Insider Trade Gap Down
MDT Medtronic	4.9478 of 5 stars	$79.15 -0.2%	$99.00 +25.1%	-6.5%	$101.86B	$36.36B	21.22	95,000	Positive News Options Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RMD) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

How does ResMed compare to Medpace?

Summary

How does ResMed compare to Encompass Health?

Summary

How does ResMed compare to Hims & Hers Health?

Summary

How does ResMed compare to Medtronic?

Summary

How does ResMed compare to Boston Scientific?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Competitors

RMD vs. MEDP, EHC, HIMS, MDT, and BSX

How does ResMed compare to Medpace?

Do analysts prefer MEDP or RMD?

Does the media refer more to MEDP or RMD?

Do insiders & institutionals believe in MEDP or RMD?

Which has more risk & volatility, MEDP or RMD?

Which has stronger valuation & earnings, MEDP or RMD?

Is MEDP or RMD more profitable?

Summary

How does ResMed compare to Encompass Health?

Do analysts rate EHC or RMD?

Which has more volatility and risk, EHC or RMD?

Which has better earnings and valuation, EHC or RMD?

Is EHC or RMD more profitable?

Is EHC or RMD a better dividend stock?

Does the media favor EHC or RMD?

Do insiders and institutionals have more ownership in EHC or RMD?

Summary

How does ResMed compare to Hims & Hers Health?

Which has higher valuation & earnings, RMD or HIMS?

Does the media prefer RMD or HIMS?

Do analysts rate RMD or HIMS?

Which has more risk & volatility, RMD or HIMS?

Is RMD or HIMS more profitable?

Do institutionals and insiders hold more shares of RMD or HIMS?

Summary

How does ResMed compare to Medtronic?

Is MDT or RMD more profitable?

Is MDT or RMD a better dividend stock?

Which has stronger valuation and earnings, MDT or RMD?

Do insiders and institutionals hold more shares of MDT or RMD?

Does the media favor MDT or RMD?

Do analysts prefer MDT or RMD?

Which has more volatility and risk, MDT or RMD?

Summary

How does ResMed compare to Boston Scientific?

Do insiders & institutionals have more ownership in RMD or BSX?

Do analysts rate RMD or BSX?

Is RMD or BSX more profitable?

Which has preferable valuation and earnings, RMD or BSX?

Which has more volatility and risk, RMD or BSX?

Does the media refer more to RMD or BSX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RMD vs. The Competition

ResMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools